Trial Profile
A retrospective study characterizing response to Rituximab in a small cohort of patients with anti-melanoma differentiation-associated gene 5 antibody Dermatomyositis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Jul 2018
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Dermatomyositis
- Focus Therapeutic Use
- 15 Jul 2018 New trial record
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism